Multiple endocrine neoplasia: Difference between revisions
| Line 5: | Line 5: | ||
==Clinical Features== | ==Clinical Features== | ||
*MEN1: | |||
**Primary [[hyperparathyroidism]] | |||
***Most common manifestation of MEN1<ref>Al-Salameh A, Cadiot G, Calender A, Goudet P, Chanson P. Clinical aspects of multiple endocrine neoplasia type 1. Nat Rev Endocrinol. 2021 Apr;17(4):207-224. doi: 10.1038/s41574-021-00468-3. Epub 2021 Feb 9. PMID: 33564173.</ref> | |||
**Pituitary adenomas | |||
**Pancreatic islet cell/GI endocrine tumors (e.g., [[Zollinger-Ellison Syndrome]], [[Insulinoma]]) | |||
*MEN2A: | |||
**Primary [[hyperparathyroidism]] | |||
**Medullary thyroid cancer | |||
**[[Pheochromocytoma]] | |||
*MEN2B: | |||
**Medullary thyroid cancer | |||
**[[Pheochromocytoma]] | |||
**Mucosal neuromas, often involving the lips and tongue | |||
==Differential Diagnosis== | ==Differential Diagnosis== | ||
Revision as of 22:45, 13 December 2022
Background
- Autosomal dominant predisposition to tumors within endocrine organs/glands
- Classified into two distinct syndromes, multiple endocrine neoplasia type 1 (MEN1), and multiple endocrine neoplasia type 2 (MEN2)
- Type 2 further subclassified into MEN2A and MEN2B
Clinical Features
- MEN1:
- Primary hyperparathyroidism
- Most common manifestation of MEN1[1]
- Pituitary adenomas
- Pancreatic islet cell/GI endocrine tumors (e.g., Zollinger-Ellison Syndrome, Insulinoma)
- Primary hyperparathyroidism
- MEN2A:
- Primary hyperparathyroidism
- Medullary thyroid cancer
- Pheochromocytoma
- MEN2B:
- Medullary thyroid cancer
- Pheochromocytoma
- Mucosal neuromas, often involving the lips and tongue
Differential Diagnosis
Evaluation
Workup
Diagnosis
Management
Disposition
See Also
External Links
References
- ↑ Al-Salameh A, Cadiot G, Calender A, Goudet P, Chanson P. Clinical aspects of multiple endocrine neoplasia type 1. Nat Rev Endocrinol. 2021 Apr;17(4):207-224. doi: 10.1038/s41574-021-00468-3. Epub 2021 Feb 9. PMID: 33564173.